On Monday, Denali Therapeutics Inc (NASDAQ: DNLI) opened lower -10.43% from the last session, before settling in for the closing price of $16.69. Price fluctuations for DNLI have ranged from $14.01 to $33.33 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 260.06% annually for the last half of the decade. Company’s average yearly earnings per share was noted -12.76% at the time writing. With a float of $125.71 million, this company’s outstanding shares have now reached $142.63 million.
In an organization with 422 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Denali Therapeutics Inc (DNLI) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Denali Therapeutics Inc is 13.43%, while institutional ownership is 88.05%. The most recent insider transaction that took place on Jan 06 ’25, was worth 247,796. In this transaction Chief Medical Officer of this company sold 12,255 shares at a rate of $20.22, taking the stock ownership to the 178,580 shares. Before that another transaction happened on Jan 07 ’25, when Company’s Chief Medical Officer sold 2,907 for $20.81, making the entire transaction worth $60,495. This insider now owns 175,673 shares in total.
Denali Therapeutics Inc (DNLI) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.71 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -12.76% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 7.03% during the next five years compared to -4.46% drop over the previous five years of trading.
Denali Therapeutics Inc (NASDAQ: DNLI) Trading Performance Indicators
Check out the current performance indicators for Denali Therapeutics Inc (DNLI). In the past quarter, the stock posted a quick ratio of 8.46.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.58, a number that is poised to hit -0.70 in the next quarter and is forecasted to reach -2.58 in one year’s time.
Technical Analysis of Denali Therapeutics Inc (DNLI)
Let’s dig in a bit further. During the last 5-days, its volume was 1.85 million. That was better than the volume of 1.1 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 29.48%. Additionally, its Average True Range was 1.37.
During the past 100 days, Denali Therapeutics Inc’s (DNLI) raw stochastic average was set at 4.87%, which indicates a significant decrease from 10.68% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 77.66% in the past 14 days, which was higher than the 65.78% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $20.66, while its 200-day Moving Average is $23.59. However, in the short run, Denali Therapeutics Inc’s stock first resistance to watch stands at $16.03. Second resistance stands at $17.10. The third major resistance level sits at $17.68. If the price goes on to break the first support level at $14.38, it is likely to go to the next support level at $13.80. The third support level lies at $12.73 if the price breaches the second support level.
Denali Therapeutics Inc (NASDAQ: DNLI) Key Stats
There are currently 145,215K shares outstanding in the company with a market cap of 2.17 billion. Presently, the company’s annual sales total 0 K according to its annual income of -422,770 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -114,750 K.
